Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction - 12/08/11
, Timothy D. Henry, MD a, b, Douglas E. Vaughn, MD c, Stephen G. Ellis, MD d, Carl J. Pepine, MD e, James T. Willerson, MD f, David X.M. Zhao, MD c, Linda B. Piller, MD g, Marc S. Penn, MD, PhD d, Barry J. Byrne, MD e, Emerson C. Perin, MD, PhD f, Adrian P. Gee, MD h, Antonis K. Hatzopoulos, MD. PhD c, David H. McKenna, MD b, John R. Forder, MD e, Doris A. Taylor, PhD b, Christopher R. Cogle, MD e, Rachel E. Olson, RN a, Beth C. Jorgenson, RN a, Shelly L. Sayre, MPH g, Rachel W. Vojvodic, MPH g, David J. Gordon, PhD i, Sonia I. Skarlatos, PhD i, Lemuel A. Moye', MD, PhD f, Robert D. Simari, MD jfor the Cardiovascular Cell Therapy Research Network (CCTRN)
Résumé |
Several previous studies have demonstrated that administration of autologous bone marrow–derived mononuclear cells (BMMNCs) improves cardiac function in patients after acute myocardial infarction (AMI). However, optimum timing of administration has not been investigated in a clinical trial. The Cardiovascular Cell Therapy Research Network was developed and funded by the National Heart, Lung, and Blood Institute to address important questions such as timing of cell delivery and to accelerate research in the use of cell-based therapies. The TIME trial is a randomized, phase II, double-blind, placebo-controlled clinical trial. The 5 member clinical sites of the Cardiovascular Cell Therapy Research Network will enroll 120 eligible patients with moderate-to-large anterior AMIs who have undergone successful percutaneous coronary intervention of the left anterior descending coronary artery and have a left ventricular (LV) ejection fraction ≤45% by echocardiography. Participants will have bone marrow aspirations and intracoronary infusions of 150 × 106 BMMNCs or placebo on day 3 or day 7 post-AMI. Objectives of this study are (1) to evaluate effects of BMMNCs on regional and global LV function compared to placebo therapy in patients with acute AMI as assessed by cardiac magnetic resonance imaging at 6 months and (2) to assess whether effects of BMMNC infusion on global and regional LV function and safety are influenced by the time of administration. This study will provide further insight into the clinical feasibility and appropriate timing of autologous BMMNC therapy in high-risk patients after AMI and percutaneous coronary intervention.
Le texte complet de cet article est disponible en PDF.Plan
| ClinicalTrials.gov no. NCT00684021. |
|
| This study is supported by the NHLBI (U01 HL087318-01) and by the Production Assistance for Cellular Therapies (N01-HB-37164). PTCA and guide catheters and wires were generously supplied by the Boston Scientific Corporation (Natick, MA). |
Vol 158 - N° 3
P. 356-363 - septembre 2009 Retour au numéro
Article précédent
- Rationale and design of the Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): A factorial, cluster-randomized trial of 2 practical cardiovascular disease prevention strategies developed for rural Andhra Pradesh, India
- Clara K. Chow, Rohina Joshi, Arun K. Gottumukkala, Krishnam Raju, Rama Raju, Srinath Reddy, Stephen MacMahon, Bruce Neal
- Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort : The IMPACT study
- John Ip, Albert L. Waldo, Gregory Y.H. Lip, Peter M. Rothwell, David T. Martin, Malcolm M. Bersohn, Wassim K. Choucair, Joseph G. Akar, Mark S. Wathen, Pooyan Rohani, Jonathan L. Halperin, for the IMPACT Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?